Endocrine Society Learning Center

Log-in / Create Account

Session Information

ENDO 09 Annual Meeting

Click here to go to the previous page

TRANSLATIONAL - Aromatase Inhibitors & Breast Cancer

Track : TRANSLATIONAL

Program Code: L06-1

Date: Friday, June 12, 2009

Time: 6:00 PM to 6:30 PM EST

SPEAKER :

AM Brodie, MS, PhD, Univ of Maryland Med Sch.
Disclosure: Nothing to disclose

Angela Brodie received her Ph.D. from the University of Manchester, UK in 1961. Later that year, she was awarded an NIH postdoctoral fellowship to join the Steroid Biochemistry Training Program at Clark University and the Worcester Foundation for Experimental Biology in Massachusetts. Dr. Brodie remained at the Worcester Foundation as Staff and Senior Scientist until1979 when she moved to the University of Maryland School of Medicine in Baltimore, MD. She is currently Professor of Pharmacology and Experimental Therapeutics in the School of Medicine and the University of Maryland Greenbaum Cancer Center. While at Worcester, Dr. Brodie began work with her husband, Harry Brodie on developing aromatase inhibitors for breast cancer treatment. Dr. Brodie�s studies demonstrated the specificity and efficacy of the lead compound as a potent aromatase inhibitor that suppressed estrogen production and induced regression of mammary tumors. Dr. Brodie�s laboratory at the University of Maryland synthesized the compound to initiate clinical trials. With collaborators at the Royal Marsden Hospital in London, this first selective aromatase inhibitor was evaluated in breast cancer patients. The efficacy and safety of aromatase inhibitors was demonstrated in advanced breast cancer and provided incentive for further trials and development of aromatase inhibitors. The success of these studies provided the proof of principle for inhibition of aromatase as an important therapeutic target for treatment of hormone-dependent breast cancer. More recently, Dr. Brodie developed a novel model system for the study of breast cancer in postmenopausal women. The model is proving to be a valuable guide for clinical studies to optimize strategies for breast cancer treatment and for understanding the mechanisms of drug resistance and sensitivity. Dr. Brodie is currently utilizing similar approaches to develop novel inhibitors to target androgen synthesizing enzymes and receptors for treating prostate cancer. Dr. Brodie has received a number of awards for her research. These include the Brinker Award from the Susan G. Komen Foundation in 2000, the General Motors Kettering Prize for Translational Research in 2005 and the American Association for Cancer Research Dorothy P. Landon Prize for Translational Research in 2006 and the Pincus medal in 2007. Dr. Brodie is actively involved in the training of scientists and physicians and has mentored more than 50 graduate students, postdoctoral fellows, and visiting faculty. She has served as a number of NIH study sections and is a frequent reviewer for NCI applications. She has also served on review panels for the DOD and as Chair for the California Breast Cancer Research Program, as well as the Cancer Research Campaign UK and other international funding agencies. Dr. Brodie has published 200 research articles, book chapters, and reviews and has six patents. Dr. Brodie has been a member of the Endocrine Society since 1963 and of American Association for Cancer Research since 1982. She is currently an Associate Editor for Cancer Research.

Audio Synchronized to PowerPoint

(Code: L06-1)

This session is a part of:

Complete Clinical and Translational Meeting Compilation (Online Access + DVD-ROM)